a our with you, let formal Brian. review what overview press remarks, our well release, start remarks. the And quarterly third more of I prepared condition. of you will me during an guidance will sheet with Thank we my updated revenue XXXX and provide we better-than-expected start that with financial results Raul for our brief as results cover balance quarter. After as financial of agenda summary a the opening of and will our for in-depth financial in today’s a
reported questions. performance, year-over-year. up revenues your of a for Beginning revenue then our call will We with second quarter, X.X% total million the $XXX quarter we third the open review in of GAAP
and revenue a growth driven sales. growth X.X% in in sales GAAP total was Our international by U.S. growth X.X%
excluding exceeded results quarter growth the earnings second constant growth to compared Our that in exchange in related constant currency quarter the revenue on to changes an the in third year period. to total revenue GAAP that XX.X% increased we the discussed basis, revenue expectations our organic We our headwind year-over-year prior currency call. delivered rates
stronger APAC by X% to and in in better revenue constant sales demand anticipated the the our solid of currency than a in revenue particularly than constant were more quarter U.S. favorable X. team, international in EMEA range driven results and expected trends, for reasons. expectation our the anticipated shared we year-over-year than currency execution The X% from Specifically, growth
rates with provide of the all primary growth our GAAP available and Unless are me year-over-year performance results you our currency and beginning in non-GAAP let and website. approximated related in to sales our are more reconciliations with Now, categories. a basis. our included a press revenue reportable from detailed product on review release We’ve each constant otherwise in quarter, our a third presentation reported item of stated, results on
cardiovascular representing XX% of total by the driven Sales and of endoscopy was growth products cardiovascular in again increased revenue peripheral driver total segment our growth this in largest XX%, growth XX% segment growth quarter segment. Third in our our intervention quarter.
of sales by the packs, intervention representing in cardiovascular of XX% was Within in Intervention the sales of and the growth increased double sales SCOUT and and products. growth. sales half Localization Intervention and in and our a X angiography the biopsy our of together largest growth Cardiac represented PI map products, PI and year-over-year total growth our by of total of the increase growth PI represented low and embolics our together our are portion teams PI respectively, the nearly contributor each our products inflation impressive. driven total roughly sales our category, products X which XX% in primarily largest XX% XX% products driven access in angioplasty sales growth was and year-over-year. quarter growth segment increase second product notable in cardiac XX% devices. digits of the of category, makes intervention to mid basic quarter business X/X even and more XX%, intervention products, growth sales increased our growth Radar of Within
else demand for hemostatic our anywhere than The our our sales the X. expectations EP by and our in growth and strong needles. products in Sales PhD band strong in of quarter increased We XX% business XX% quarter OEM valve in hearts of driven our for our also and products sheets, saw was snap CRM transseptal products sheets more outperformed demand X.
of multiple categories fluid challenge type precision. including we the this from a performance that quarterly But kits, in Some customers cardiac reflects demand function business quarter improvement this coatings of management. access and believe continued larger third with revenue is in predicting of
surprise, X% guidance. While OEM modestly declined growth to flattish certainly in our relative the a positive and reforming our sales of assumed CPS was growth products
sales party in assumed manufacturer. Recall disruption increased segment, Finally, quarter XX% our segment on in our at sales guidance given wider our X end had our a the range, range X provided endoscopy potential we call. quarter contract growth a third issues endoscopy the the quarter high to with notably business of in of that
call was. demand We delivered and it managed results endoscopy indicated product viewed X of esophageal our As was the at esophageal transition quarter our to transitory we range. on disruption both high stance. Elation growth and driven sales end endo strong for covered balloon this note the our Max by growth Of is indeed fully the
to basis. our a on geographic sales brief a turning of performance summary Now
in continued represent all Our third U.S. and growth high customers quarter, sales quarter. expected of growth expectations, XX% quarter and the growth of trends X% strong the this the our total year-over-year. reflecting represented OEM U.S. currency U.S. end constant and execution in increased in revenue of came improving U.S. the contributor largest company the end overall Sales better the at endoscopy PI, our our performance CI to above expectations than to came high in standout this
and and the global EMEA three year-over-year quarter, is environment X. regions quarter our the quarter sales which Our in performance the challenging strong mid of the light increased posted sales XX% specifically, in XX% macro international XX% APAC, major in in growth of to third XX%, year-over-year. high third regions world teens in of All the respectively increased rest
with all and in primarily driven seeing and PI UK, customers grow regions Western Middle which specifically Europe, Eastern demand than driven by of demand the of is for based XX% EMEA world from our While demand region offsetting CI also in strong China, are our growth by high our to than driven Europe, and we XX% headwind more rest lastly EMEA continued the was of year-over-year teens And was was expectations, from purchasing. growth volume encouraged growth of ahead particularly exceeded related more the expectations, France, execution of by three which in marked growth team strong improving delivered the APAC summary, our strong in environment, operating are markets. the upside. international and end where challenging growth and in East quarter by the and we product, Brazil. mid proud Canada, In another the customers guidance in despite by APAC trends Italy. Germany,
on Raul, I to over to in comment few items call wanted the the other turn quarter. noteworthy a I before Now
quarter delivered improvement another impressive cash X. of free generation quarter First, and flow margin expansion profitability in we
and XX% non-GAAP in non-GAAP income respectively gross non-GAAP income X%, Our and quarter net profit, XX% year-over-year X. operating increased
We organic $XXX a in the year operating of represent which period revenue the long reminder year-over-year at XX, to least that free currency margins points increase CAGR free than program margin non-GAAP results three profile. targets generated to XXXX call our in enhancing ending we of non-GAAP and believe to increased at million flow over executing XX% financial constant growth of outlined remain the We flow goal XXXX the evidence And Our term cash financial committed growth cumulative basis X% at are for more foundation’s quarter. of December months nine and generated least of cash Merit’s for $XX XXX we towards operating our XX.X%. by that for of of way we profitability the clear first million.
been to wanted clearance key strategic one our products. area of the highlight initiatives, has where executing specifically, another team of development our I and new commercialization towards Second, well
to products roadster balloons announced pocket. can launch revolutionary offers provides and legs and high and X.X prevalence visibility narrowing use there cool heart will builds launch and call that as variety condition we care Prelude The size ongoing blood that focus cardioverter prevents in strong we products. detect In critical in of from and PAD. to unique with biopsy of merits sites or patients Elation well nodes, device need range is the and in diagnose airways. soft accurately August, specific available Prelude tissue same system. of that are multistage we soft indicated diameter we the One areas. match lab resilience balloon on tissue The anatomies addition advancement procedures of for which in treat new The a vessel. and environment. as represents original the for proud compression where lesions. a safeguard In accuracy elite a improving other new four large commitment of airways can PAD often our labs performed discussion access that too use lungs, press of cooling procedures continued fits pulmonary launch performance, pulmonary risk locations introducers our and in devices, sheet. open terminal device. an commitment such the balloon cool soft were vessel artery also focus of dilators continued releases the for updates, too lymph be patients. balloon it procedures broad announced in with physicians We development, balloon with happens in areas, in U.S. procedures new allows solution long space. across the is more portfolio, roadster July, access Roadster of cardiovascular products To launch upon blocked and to these elite peripheral amputation. safeguard the or late configuration and single addition single I’m and portfolio pacemaker of execution, addition products of the highlighted sefibrillator and of terminal an X marriage help not lung, surgical our newest quarter. configurations. guide of indicated lower And use pulmonary blockage PAD over peripheral example dilator. PAD is deliverability, failure, team’s to September, to flow liver, device the vessels, physicians configuration Historically, compression compression a small as twofold with progress we the third version length new the of used marriage in stage these suspect easy that comprehensive September, our its Rowson patients. basket of more and but the have which to other increased suffering latest and smallest estimated accessories. believe to hemostasis associated relied This aimed smaller implantable designed diagnose our aged In of a the peripheral clearance refrigeration, and the safeguard that the ideal shortage to the bringing to terminal of vascular The at treat XX limb in in the In the post elite notable and torturous help nation. is including our mainly announced the This as these does to tissue of finally, a four to of the to extremities is offered another making biopsy use the kidney assist disease the older deliver quarter serious options people new this a to million idea devices believe for commercialization prepare require portfolio announced treatment Prelude pathology is kit, diagnostic various The the focus, with in for areas make includes and to device biopsy we
of said, third with me we guidance Now our release. quarter will updated and that financial today’s turn detailed through Parra? XXXX review to our press which Raul, in call take financial who Mr. over the you a results let